Navigation Links
FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)
Date:7/8/2009

WOODCLIFF LAKE, N.J., July 8 /PRNewswire/ -- Eisai Corporation of North America today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental new drug application (sNDA) for an alternative five-day dosing regimen for Dacogen(R) (decitabine for injection) to treat patients with myelodysplastic syndromes (MDS). MDS is a potentially life-threatening group of bone marrow diseases that limit the production of functional blood cells.

Currently, Dacogen is approved for use as a three-day regimen, administered at a dose of 15 mg/m2 via continuous IV infusion over three hours repeated every eight hours for three consecutive days per cycle. The cycle is repeated every six weeks. The alternative five-day dosing regimen of Dacogen(R) submitted to the U.S. FDA is a single daily dose with a significantly reduced administration time. If approved, patients with MDS may experience increased convenience with the new dosing regimen.

"We're pleased that the FDA has agreed to review our application for the alternative dosing regimen, and we look forward to working with the agency throughout the review process," said Cynthia Schwalm, President of Eisai Inc. "This application is one part of a full complement of clinical development programs we have committed for Dacogen and is a vital part of our human health care mission of increasing patient benefits and fulfilling unmet medical needs."

Acceptance of the sNDA means that FDA has found the company's submission to be sufficiently complete to review.

About Dacogen

The safety profile of decitabine for injection is well characterized. Dacogen (decitabine for injection) was approved by the FDA on May 2, 2006, and is indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-Ameri
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Accepts Arno Therapeutics IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
2. Food and Drug Administration Accepts Isolagens Biologics License Application for Full Review
3. FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)
4. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
5. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
6. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
7. New Heart Ultrasound Research Reveals Life-Saving Treatment Alternatives and Advancements for Heart Patients
8. Researchers at the Karmanos Cancer Institute in Detroit Discover Feasibility of Chemotherapy Alternative
9. Gallbladder Removal Through Vagina Offers Minimally Invasive Alternative
10. Comprehensive Safety Tests Published on Ruyan(R) Smoking Alternatives
11. Encorium Announces the Initiation of a Strategic Partnership With Prologue Research After the Postponement of Negotiations Regarding Its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investig
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2010)... DATATRAK International, Inc. (OTCQX: DATA), a ... solutions for the clinical trials industry, today announced ... Connect Partner, will co-sponsor a seminar in ... for the clinical trials industry. The topics addressed ... challenges, costs and obstacles customarily encountered in implementing ...
(Date:2/9/2010)... 9 Hoya,announces the appointment of Mr. ... starting the 1st of April 2010 . He will ... leading the European branch in the past 5 years. Mr.,Bottero ... Mr. Werquin has 20 years experience in ... and Hoya Lens France. Based in, Paris , he will ...
(Date:2/8/2010)... LOUIS , Feb. 8 Cost ... Healthcare Products (Nasdaq: AHPI ) narrowly back into ... ,, Sales for the quarter ended December 31, ... $12.5 million during the same quarter last year ... However, Allied,s costs of sales were reduced even more ...
Breaking Medicine Technology:DATATRAK International and PFC Pharma Focus to Co-Sponsor eClinical Solutions Seminar in Tel Aviv 2DATATRAK International and PFC Pharma Focus to Co-Sponsor eClinical Solutions Seminar in Tel Aviv 3DATATRAK International and PFC Pharma Focus to Co-Sponsor eClinical Solutions Seminar in Tel Aviv 4New CEO for Hoya Vision Care Europe 2Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 2Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 3Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 4Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 5Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 6Greater certainty in monitoring 3 therapeutic medications is facilitated by new CRMs 61640 1Greater certainty in monitoring 3 therapeutic medications is facilitated by new CRMs 61640 2Saliva proteins change as women age 10796 1Berkeley Lab lends expertise to India to promote energy efficiency 10792 1Berkeley Lab lends expertise to India to promote energy efficiency 10792 2Berkeley Lab lends expertise to India to promote energy efficiency 10792 3Berkeley Lab lends expertise to India to promote energy efficiency 10792 4Berkeley Lab lends expertise to India to promote energy efficiency 10792 5
(Date:2/9/2010)... Minn. , Feb. 9 ... obstructive pulmonary disease (COPD), is now being measured ... Health Tracking Program. The program focuses on three ... that can be triggered or made worse by ... air pollution — asthma, heart attacks and COPD. ...
(Date:2/9/2010)... Gift for the ... CHICAGO , Feb. 9 ... giving a gift for the heart with ... and Flavorful Recipes Made with Canola Oil" by the ... some of these recipes for love or give the ...
(Date:2/9/2010)... In conjunction with the 2010 Super Bowl, ... (LSI) sponsored the first-annual Gridiron Greats Night of Champions, a ... Mike Ditka and Jamie Foxx . Supported ... Greats is a non-profit organization that provides financial assistance and ... This year, Gridiron Greats recognized LSI at the event as ...
(Date:2/9/2010)... Slone Epidemiology Center have found a direct link ... 2 diabetes in African American women. The study, ... of Epidemiology , is the first prospective study ... and incidence of type 2 diabetes in a ... Type 2 diabetes is estimated to affect 20.6 ...
(Date:2/9/2010)... University Hospitals (UH) Case Medical Center, have published new ... care for patients with locally advanced cervical cancer. ... Cancer Research, the phase one study found that ... combination with standard-of-care cisplatin chemotherapy and radiation treatment in ... reduction in cancer disease and cancer control. , ...
Breaking Medicine News(10 mins):Health News:Minnesota Department of Health Report: Nearly 6,000 Hospitalizations for COPD in 2007 2Health News:Cook With Love This Valentine's Day With Heart-Smart Recipes 2Health News:Cook With Love This Valentine's Day With Heart-Smart Recipes 3Health News:Laser Spine Institute Honored at the Gridiron Greats Night of Champions 2Health News:Neighborhood socioeconomic status and diabetes 2
... the footsteps of banks and insurance services, British universities ... companies and institutions in order to reduce the costs. ... Council for Industry and Higher Education (CIHE), that is ... India and elsewhere was inevitable if British universities wanted ...
... company is one of the leading search engines is ... politician sued Google. He said that the company is ... Toback, a member of the Nassau County Legislature accused ... minors. In regard to this a legal complaint is ...
... nations in banning poultry products from Britain. The Times of ... even breeding birds from Britain. // While Hong Kong has ... flu alert. ,Peter Mandelson, the European Trade Commissioner, ... accept most British poultry imports and to restrict produce from ...
... Organization says that smoke from cooking fuel is one of ... // Authorities of the WHO feel that an investment in ... seven times over. ,The organization is of the ... cook with solid fuels, and many a times breathing in ...
... University that chose to study the mind-set of gay men who ... opening up to others about their HIV status. // ... says, “I was very surprised at how little regret we found, ... carefully on whether or not to tell people. The results offer ...
... Baeg Moon-hong. He is a senior researcher at the Korea ... was show cased in an exhibition at the Seoul Education ... meters tall. The special features are that it can understand ... expressions. , The first android was made by ...
Other Medicine News:Health News:British Varsities To Outsource Admin And Research To India 2
An economical solution to the need to provide wrap-around protection. The one-sided velcro closure allows greater flexibility in sizing. Front protection is 0.5mm Pb and the back is 0.25mm Pb equival...
This wrap around apron features a uniquely designed orthopedic wide belt that is integrated directly on the apron....
The most comfortable and easy to use apron in the industry. This front protection apron comes with a fully adjustable snap-on 5" orthopedic belt to relieve weight off your shoulders. Velcro strap acr...
Unique criss-cross strapping. The MSV-10 is our most popular model. Extra wide Velcro ensures a wide variety of adjustments and easy closing....
Medicine Products: